Dr. Rodriguez begins this segment by explaining that the Myeloma Clinic was originally jointly managed with Transplant Leukemia services. She served as Clinic Chief of the Lymphoma/Myeloma Section from 1994−1996. Dr. Rodriguez explains what she learned from working in this environment of shared resources and how she acquired basic knowledge of how to assess patient volume and flow and determine hours of clinic operation. Next Dr. Rodriguez explains how the administrative issues shifted once the Myeloma Clinic became autonomous in 2003 and was stressed with challenged of internal utilization of resources. At this point she began her habit of writing reports to ensure transparency. (She notes that she used to have access to downstream re...
Dr. Cox gives an overview of issues involved in setting up regional care centers and sister institut...
Dr. Alexanian discusses his work with erythropoeinin and its impact. He then talks about how myeloma...
Dr. Alexanian discusses the transplant supported program in myeloma. He sketches the history of the ...
Dr. Rodriguez begins this segment by explaining that the Myeloma Clinic was originally jointly manag...
In this segment, Dr. Rodriguez talks about the important role that physician-leaders can serve in an...
Ms. Houston begins this segment by briefly describing what led her 1997 decision to shift from nursi...
In this chapter, Dr. Balch talks about factors contributing to MD Anderson\u27s financial instabilit...
Dr. Rodriguez begins this segment by explaining how her view of the institution changed as she stepp...
At the beginning of the chapter, Dr. Alexanian and the interviewer review CV entries for relevance t...
In this segment, Dr. Rodriguez sketches how she began to shift away from research as her main focus....
Dr. Becker shifts to administrative topics, first noting the advantages MD Anderson gains from havin...
Ms. Houston talks about how MD Anderson did not offer much leadership development support in the sev...
Dr. Cohen begins by explaining that he had the vision of turning the Integrative Medicine Center int...
Dr. Elting talks about how her interest in value of care evolved. She sets context by noting that in...
Dr. Escalante talks about MD Anderson’s section of General Internal Medicine (GIM), the first to ope...
Dr. Cox gives an overview of issues involved in setting up regional care centers and sister institut...
Dr. Alexanian discusses his work with erythropoeinin and its impact. He then talks about how myeloma...
Dr. Alexanian discusses the transplant supported program in myeloma. He sketches the history of the ...
Dr. Rodriguez begins this segment by explaining that the Myeloma Clinic was originally jointly manag...
In this segment, Dr. Rodriguez talks about the important role that physician-leaders can serve in an...
Ms. Houston begins this segment by briefly describing what led her 1997 decision to shift from nursi...
In this chapter, Dr. Balch talks about factors contributing to MD Anderson\u27s financial instabilit...
Dr. Rodriguez begins this segment by explaining how her view of the institution changed as she stepp...
At the beginning of the chapter, Dr. Alexanian and the interviewer review CV entries for relevance t...
In this segment, Dr. Rodriguez sketches how she began to shift away from research as her main focus....
Dr. Becker shifts to administrative topics, first noting the advantages MD Anderson gains from havin...
Ms. Houston talks about how MD Anderson did not offer much leadership development support in the sev...
Dr. Cohen begins by explaining that he had the vision of turning the Integrative Medicine Center int...
Dr. Elting talks about how her interest in value of care evolved. She sets context by noting that in...
Dr. Escalante talks about MD Anderson’s section of General Internal Medicine (GIM), the first to ope...
Dr. Cox gives an overview of issues involved in setting up regional care centers and sister institut...
Dr. Alexanian discusses his work with erythropoeinin and its impact. He then talks about how myeloma...
Dr. Alexanian discusses the transplant supported program in myeloma. He sketches the history of the ...